Overview

Metronomic Low-Dose Cyclophosphamide and Methotrexate With or Without Bevacizumab in Treating Women With Metastatic Breast Cancer

Status:
Completed

Trial end date:
2009-08-01

Target enrollment:

Participant gender:

Summary

This randomized phase II trial is studying metronomic low-dose cyclophosphamide and methotrexate to see how well they work compared to metronomic low-dose cyclophosphamide, methotrexate, and bevacizumab in treating women with metastatic breast cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Dana-Farber Cancer Institute

Collaborators:

Genentech, Inc.
National Cancer Institute (NCI)

Treatments:

Bevacizumab
Cyclophosphamide
Methotrexate